| Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287) |
|---|
| 01/31/2002 | CA2415362A1 Method for treating fibrotic diseases or other indications |
| 01/31/2002 | CA2415077A1 Cell cycle proteins and mitosis-associated molecules |
| 01/31/2002 | CA2415054A1 Cyanomethyl substituted thiazoliums and imidazoliums and treatments of disorders associated with protein aging |
| 01/31/2002 | CA2412626A1 Il-17 molecules and uses thereof |
| 01/30/2002 | EP1175900A2 Use of growth hormone secretagogues for improvement of fucnctional health status |
| 01/30/2002 | EP1175498A2 Nucleic acid-antibody conjugate for delivering a foreign nucleic acid in cells |
| 01/30/2002 | EP1175446A1 Human antibodies that bind human il-12 and methods for producing |
| 01/30/2002 | EP1175412A1 Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents |
| 01/30/2002 | EP1175216A2 Antimalarian agents for the treatment of asthma |
| 01/30/2002 | EP1175214A2 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect |
| 01/30/2002 | EP1175213A2 Heterocyclic aromatic compounds useful as growth hormone secretagogues |
| 01/30/2002 | EP0904284B1 6-substituted amino-4-oxa-1-azabicyclo[3.2.0]heptan-7-one derivatives as cysteine protease inhibitors |
| 01/30/2002 | CN1333784A Benzylmaltosides as inhibitors of smooth muscle cell proliferation |
| 01/30/2002 | CN1333778A Benzylmaltotriosides as inhibitors of smooth muscle cell proliferation |
| 01/30/2002 | CN1333684A Use of 5HT3 receptor antagouists for the treatment of chronic fatigue syndrome |
| 01/30/2002 | CN1333019A Injection for treating traumatic injury |
| 01/27/2002 | CA2353768A1 Use of growth hormone secretagogues for improvement of functional health status |
| 01/24/2002 | WO2002006288A1 Tetrahydro-heterocycloazepinyl pyrimidine derivatives |
| 01/24/2002 | WO2002006284A1 Indoloquinazolinones |
| 01/24/2002 | WO2002006254A1 Tetrazole derivatives |
| 01/24/2002 | WO2002005841A1 Treatment of glycogen storage disease type ii |
| 01/24/2002 | WO2002005840A1 Medicinal compositions for promoting fixation of transplanted cells |
| 01/24/2002 | WO2002005797A2 Use of dopamine d2/d3 receptor agonists to treat fibromyalgia |
| 01/24/2002 | WO2002005786A1 Pharmaceutical composition improved in peroral absorbability |
| 01/24/2002 | WO2001046258A3 Transporters and ion channels |
| 01/24/2002 | WO2001032910A3 27 human secreted proteins |
| 01/24/2002 | WO2001019860A3 Proteins associated with cell differentiation |
| 01/24/2002 | WO2001019855A3 Pharmaceutical compositions and methods of using secreted frizzled related protein |
| 01/24/2002 | WO2001012819A3 Protein phosphatases and diagnosis and treatment of phosphatase-related disorders |
| 01/24/2002 | WO2001000655A3 Therapeutic peptides derived from subsequences of bpi |
| 01/24/2002 | US20020010949 Cloning using donor nuclei from differentiated fetal and adult cells |
| 01/24/2002 | US20020010216 Mixture of norepinephrine reuptake inhibitors and antimuscarinic agents; treating disorders or diseases of the central nervous system, and particularly useful in treating incontinence. |
| 01/24/2002 | US20020010170 Pyrimido(1,6-b)pyridazine derivatives used as p38 inhibitors a mammalian protein kinase is involved in cell proliferation, cell death and response to extracellular stimuli |
| 01/24/2002 | US20020010138 Treatment of neuromuscular disorders and conditions with different botulinum |
| 01/24/2002 | CA2415673A1 Tetrazole derivatives |
| 01/23/2002 | EP1173767A1 Peptide epitopes recognized by disease promoting cd4+ t lymphocytes |
| 01/23/2002 | EP1173587A1 Dsp-10 dual-specificity map kinase phosphatase |
| 01/23/2002 | EP1173586A1 Dsp-8 dual-specificity map kinase phosphatase |
| 01/23/2002 | EP1173568A2 Laminin 2 and methods for its use |
| 01/23/2002 | EP1173566A2 Human membrane-associated proteins |
| 01/23/2002 | EP1173479A1 49 human secreted proteins |
| 01/23/2002 | EP1173477A1 49 human secreted proteins |
| 01/23/2002 | EP1173465A1 Novel human voltage-gated potassium channel |
| 01/23/2002 | EP1173462A1 50 human secreted proteins |
| 01/23/2002 | EP1173440A1 Tetracyclic azepinoindole compounds as 5-ht receptor ligands |
| 01/23/2002 | EP1173432A1 Piperidine-indole compounds having 5-ht6 affinity |
| 01/23/2002 | EP1173215A1 Over-coated chewing gum formulations |
| 01/23/2002 | EP1173170A1 Pyrrolidine modulators of chemokine receptor activity |
| 01/23/2002 | EP1173169A1 Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof |
| 01/23/2002 | EP1173162A1 Compositions of boswellic acids derived from boswellia serrata gum resin, for treating lymphoproliferative and autoimmune conditions |
| 01/23/2002 | EP1173149A1 Cosmetic and/or dietetic composition comprising a mixture of lycopene and olive leaf extract |
| 01/23/2002 | CN1332740A 5HT antagonists for antidepressant therapy |
| 01/23/2002 | CN1332724A N-arylsulfonyl amino acid omega amides |
| 01/23/2002 | CN1332711A Vitamin D analogues |
| 01/23/2002 | CN1332628A Method of treating sexual disturbances |
| 01/23/2002 | CN1331984A External-use trauma treating ointment |
| 01/17/2002 | WO2002004625A1 α-SYNUCLEIN BINDING PROTEIN |
| 01/17/2002 | WO2002004612A2 Drug metabolizing enzymes |
| 01/17/2002 | WO2002004520A2 Transporters and ion channels |
| 01/17/2002 | WO2002003996A1 Use of dammarane-type tritepenoid saporins |
| 01/17/2002 | WO2001081309A3 4-benzyl-1-[2-(4-hydroxy-phenoxy)-ethyl]-piperidine-3,4-diol |
| 01/17/2002 | WO2001062726A3 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses |
| 01/17/2002 | WO2001019817A3 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission |
| 01/17/2002 | WO2001012598A3 METHODS OF INHIBITING BINDING OF β-SHEET FIBRIL TO RAGE AND CONSEQUENCES THEREOF |
| 01/17/2002 | WO2001007471A3 Cell cycle and proliferation proteins |
| 01/17/2002 | WO2000078953A3 Human transport proteins |
| 01/17/2002 | WO2000078952A3 Human rna metabolism proteins (rmep) |
| 01/17/2002 | US20020007075 Neurological disorders including physically damaged nerves and neurodegenerative diseases, and for treating alopecia and promoting hair growth; Alzheimer's, Parkinson's disease; amyotrophic lateral sclerosis |
| 01/17/2002 | US20020006951 Solid-state form of celecoxib having enhanced bioavailability |
| 01/17/2002 | US20020006448 Compositions and methods for treating back and leg discomfort |
| 01/17/2002 | CA2415808A1 Transporters and ion channels |
| 01/17/2002 | CA2414387A1 Drug metabolizing enzymes |
| 01/16/2002 | EP1172106A2 Use of fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles as substance P receptor antagonists |
| 01/16/2002 | EP1171622A1 Cassette regulating the expression of a heterologous nucleic acid in a eucaryotic cell, especially a muscle cell |
| 01/16/2002 | EP1171616A1 Method for enhancing myoblast migration and invasion in the context of gene therapy |
| 01/16/2002 | EP1171614A1 Dsp-4 dual-specificity map kinase phosphatase |
| 01/16/2002 | EP1171613A1 Dsp-7 dual-specificity map kinase phosphatase |
| 01/16/2002 | EP1171579A1 Human tumor necrosis factor receptor tr9 |
| 01/16/2002 | EP1171457A1 46 human secreted proteins |
| 01/16/2002 | EP1171160A1 Method and means for treating post-polio syndrome |
| 01/16/2002 | EP1171136A2 Immunomodulating composition for use especially in the treatment of inflammations, infections and surgical adhesions |
| 01/16/2002 | EP1171130A1 Pharmaceutical compositions containing poly(adp-ribose) glycohydrolase inhibitors and methods of using the same |
| 01/16/2002 | EP1171115A1 Methods of delivery of cetyl myristoleate |
| 01/16/2002 | CN1331801A Kidney disease detection and treatment |
| 01/16/2002 | CN1331688A Aminopyrazole derivatives |
| 01/16/2002 | CN1331674A Sulfonamide hydroxamates |
| 01/16/2002 | CN1331597A Use of bisphosphonates for prevention and treatment of infectious processes |
| 01/16/2002 | CN1331589A Oral creating supplementation for treating or preventing muscle disuse syndrome |
| 01/15/2002 | US6339160 For therapy of tumoral growth and metastatization, aterosclerosis, multiple sclerosis, alzheimer's disease, osteoporosis, hypertension, rheumatoid arthritis and other inflammatory diseases |
| 01/15/2002 | US6339095 Therapeutic use of 1, 6-dimethyl-8β-hydroxymethyl-10-α-methoxyergoline |
| 01/15/2002 | US6339093 For therapy of neurodegeneration; used as nmda(n-methyl-d-aspartate)-receptor subtype selective blockers |
| 01/10/2002 | WO2002003073A1 Differential diagnosis of neurological diseases |
| 01/10/2002 | WO2002002771A2 Human sparc-homologous (hsparc-h1) gene and methods and uses thereof |
| 01/10/2002 | WO2002002757A2 Adenylyl and guanylyl cyclases |
| 01/10/2002 | WO2002002744A2 Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof |
| 01/10/2002 | WO2002002638A2 Methods for treating rheumatic diseases using a soluble ctla4 molecule |
| 01/10/2002 | WO2002002634A2 Human extracellular matrix and cell adhesion polypeptides |
| 01/10/2002 | WO2002002633A2 Transporters and ion channels |
| 01/10/2002 | WO2002002603A2 Protein modification and maintenance molecules |
| 01/10/2002 | WO2002002587A1 B7-like polynucleotides, polypeptides, and antibodies |